ALLSCHWIL, Switzerland, Nov. 28, 2005 (PRIMEZONE) -- Actelion Ltd (Swiss:ATLN.SW - News) (Other OTC:ALIOF.PK - News) today announced that in the BUILD program with bosentan (Tracleer(R)) in patients suffering from either idiopathic pulmonary fibrosis (IPF) (BUILD-1) or pulmonary fibrosis related to Systemic Sclerosis (BUILD-2), no effect was shown on the primary endpoint of exercise improvement as measured by the 6-minute-walk test.
